arrow
D

Deborah B. Doroshow

ica hn school of medicine at mount sinai
H指数:24
被引数:6,862

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02

曲妥珠单抗德鲁替康在HER2表达型胆道或胰腺肿瘤患者中的疗效与安全性:DESTINY-PanTumor02研究的亚组分析

2026-07-300
OA
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trial

靶向治疗DNA损伤反应和同源重组修复缺陷:奥拉帕利联合治疗试验

Cancer
IF5.1
2026-03-110
PRE
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶1 (IDH1) 和IDH2-mutant胆管癌: 来自美国国家癌症研究所10129期2试验的安全性和抗肿瘤活性

CANCER
IF5.1
2025-02-070
PRE
Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers

Cyclin E1/CDK2的激活定义了妇科癌症中WEE1激酶抑制的关键易损性。

2025-01-040
OA
Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor
2024-04-050
PRE
NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors
2023-12-012
PRE
Factors associated with enrollment, participation, and survival of patients on early phase cancer clinical trials
2023-12-011
PRE
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership
2023-06-264
OA
Rescuing response to ICI by blocking the type-2 immune axis in patients with NSCLC progressing on immunotherapy: A phase 1b/2 trial of dupilumab administered with checkpoint blockade
2023-04-140
PRE
Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting
2023-04-142
PRE
NEOADJUVANT NIVOLUMAB COMBINED WITH CCR2/5 INHIBITOR OR ANTI-IL-8 ANTIBODY IN NON-SMALL CELL LUNG CANCER AND HEPATOCELLULAR CARCINOMA
2022-11-072
OA